TrialSpark and Pfizer partner to accelerate clinical trials

18th September 2019 (Last Updated December 23rd, 2019 08:35)

Pfizer will extend its clinical trials to community doctors who have not previously been involved in any study investigations after the company signed a multi-year collaboration with TrialSpark.

Pfizer will extend its clinical trials to community doctors who have not previously been involved in any study investigations after the company signed a multi-year collaboration with TrialSpark.

Technology company TrialSpark collaborates with doctors to create Good Clinical Practice (GCP) / International Conference on Harmonization (ICH) compliant clinical trial sites in their existing practices.

The company provides training, technology and research staff to doctors to execute high quality clinical trials.

Pfizer chief development officer Rod MacKenzie said: “To accelerate the delivery of innovative new medicines to those who are waiting for them, we need to make our trials accessible to more people. Pfizer is working within our own organisation and with partners to pursue multiple novel approaches to expanding access.

“We hope that our collaboration with TrialSpark will enable us to reach patients who otherwise may have been unaware of or unable to participate in a Pfizer clinical trial.”

Pfizer teamed up with TrialSpark to strengthen its aim of creating clinical trial sites with doctors seeking eligible patients to participate in a clinical programme.

Using aggregated data to identify geographical clusters with a significant number of patients, the two companies can identify potential new sites and respective training needed to run a trial.

The collaboration is currently engaged in clinical trials in the fields of inflammation and immunology, with programmes underway in vitiligo, atopic dermatitis, alopecia, and psoriasis.

TrialSpark CEO and co-founder Benjamine Liu said: “Doctors in our network are motivated by the opportunity to offer investigational medicines to their patients who would otherwise not have access to them and contribute to the advancement of new medicines.

“Allowing doctors to bring clinical trials directly to their patients should reduce the time and financial costs of accessing novel investigational medicines and make trials accessible to patients and doctors who have traditionally been difficult to reach.”